Recurrent Ovarian Carcinoma Active Not Recruiting Phase 1 / 2 Trials for Vistusertib (DB11925)

IndicationStatusPhase
DBCOND0030000 (Recurrent Ovarian Carcinoma)Active Not Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02208375mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianTreatment